Read More

FDA Has Granted Breakthrough Therapy Designation To Moderna’s Respiratory Syncytial Virus Vaccine Candidate, mRNA-1345

The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.The designation is based on topline data from the ConquerRSV Phase 3 efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease.

MRNA